Capricor Announces Preclinical Results

NEW ORLEANS, LA--(Marketwire - November 11, 2008) - Capricor Inc. (www.capricor.com) announced today the results from preclinical studies showing that its cardiosphere-derived stem cells (CDCs), when transplanted into a well-established mouse model of myocardial infarction (MI), protect the heart significantly better against progressive degeneration following MI or heart attack than do highly purified cardiac stem cells or heart derived mesenchymal like progenitor cells.